A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.

MLA

Berends, Cécile L., et al. “A Novel Sustained-Release Cysteamine Bitartrate Formulation for the Treatment of Cystinosis: Pharmacokinetics and Safety in Healthy Male Volunteers.” Pharmacology Research & Perspectives, vol. 9, no. 2, Apr. 2021, p. e00739. EBSCOhost, https://doi.org/10.1002/prp2.739.

APA

Berends, C. L., Pagan, L., van Esdonk, M. J., Klarenbeek, N. B., Bergmann, K. R., Moerland, M., van der Wel, V., de Visser, S. J., Büller, H., de Loos, F., de Vries, W. S., Waals, H., de Leede, L. G. J., Burggraaf, J., & Kamerling, I. M. C. (2021). A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers. Pharmacology Research & Perspectives, 9(2), e00739. https://doi.org/10.1002/prp2.739

Chicago

Berends, Cécile L, Lisa Pagan, Michiel J van Esdonk, Naomi B Klarenbeek, Kirsten R Bergmann, Matthijs Moerland, Vincent van der Wel, et al. 2021. “A Novel Sustained-Release Cysteamine Bitartrate Formulation for the Treatment of Cystinosis: Pharmacokinetics and Safety in Healthy Male Volunteers.” Pharmacology Research & Perspectives 9 (2): e00739. doi:10.1002/prp2.739.